目的：比较观察免疫组化（ IHC）法检测乳腺癌组织中HER-2蛋白表达和荧光原位杂交（ FISH）法检测其HER-2基因扩增在乳腺癌分子靶向治疗中的临床意义。方法采用IHC法及 FISH法分别检测111例乳腺癌组织中HER-2蛋白表达及HER-2基因扩增情况。结果111例乳腺癌标本中，HER-2蛋白（+++）者53例（，++）者47例，（+）或（-）者11例；基因扩增74例，未扩增37例。2种检测结果呈正相关关系（rs ＝0.625，P﹤0.05）。结论 IHC法检测HER-2蛋白可作为乳腺癌患者是否应用赫赛汀的初筛，HER-2蛋白表达阳性的患者有必要进一步进行HER-2基因扩增检测，来确定临床治疗是否应用赫赛汀。%Objective To explore the clinical significance of HER-2 protein expression detected by immunohis-tochemistry( IHC)and HER-2 gene amplification detected by fluorescence in situ hybridization( FISH)in molecular targeting therapy of breast cancer. Methods The HER-2 protein expressions and the HER-2 gene amplification in the 111 cases of breast cancer tissues were detected by IHC and FISH,respectively. Results The numbers of pa-tients showed IHC( +++),IHC( +++)and IHC( +/ -)were 53 cases,47 cases and 11 cases,respectively. The HER-2 gene amplification existed in the 74 cases,no amplification existed in the 37 cases. There was positive corre-lation between the two results(rs =0. 625,P﹤0. 05). Conclusion Before herceptin therapy,the immunohistoche-mistry can be first used to detect the HER-2 protein expressions,and then in the cases woth positive expressions of HER-2,the HER-2 gene amplifications should be further tested to guide the herceptin therapy in the treatment of breast cancer.
展开▼
